Clearmind Medicine Patent Application Published
Ticker: CMND · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1892500
Sentiment: neutral
Topics: patent, pharmaceuticals, mental health
TL;DR
Clearmind's ketamine combo treatment patent application is out, could be big for addiction therapy.
AI Summary
Clearmind Medicine Inc. announced on August 29, 2024, that its patent application for an innovative ketamine-based combination treatment has been published. This publication relates to a novel approach for treating conditions such as alcohol use disorder and opioid use disorder.
Why It Matters
The publication of this patent application signifies a step forward in Clearmind's intellectual property strategy for its novel ketamine-based treatments, potentially impacting its competitive position in the mental health therapeutics market.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical development stage, and patent publications do not guarantee eventual market approval or commercial success.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- August 29, 2024 (date) — Announcement Date
- 001-41557 (other) — SEC File Number
FAQ
What is the subject of the published patent application?
The published patent application is for an innovative ketamine-based combination treatment for conditions such as alcohol use disorder and opioid use disorder.
When was the press release announcing the patent publication issued?
The press release was issued on August 29, 2024.
What form is Clearmind Medicine Inc. filing with the SEC?
Clearmind Medicine Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is Clearmind Medicine Inc.'s fiscal year end?
Clearmind Medicine Inc.'s fiscal year end is October 31.
Where are Clearmind Medicine Inc.'s principal executive offices located?
Clearmind Medicine Inc.'s principal executive offices are located at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Filing Stats: 263 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-08-29 16:30:02
Filing Documents
- ea021290702-6k_clearmind.htm (6-K) — 11KB
- ea021290702ex99-1_clearmind.htm (EX-99.1) — 13KB
- image_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-073910.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: August 29, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer